Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

Benzinga · 1d ago
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.